These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25692620)

  • 21. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
    Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
    PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.
    Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF
    Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
    Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical role for the mTORC2 pathway in lung fibrosis.
    Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
    PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
    Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
    Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.
    Benavides-Serrato A; Lee J; Holmes B; Landon KA; Bashir T; Jung ME; Lichtenstein A; Gera J
    PLoS One; 2017; 12(4):e0176599. PubMed ID: 28453552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.